Immucor Goodwill Valuation Analysis

	Immucor, Inc. (NASDAQ: BLUD) is the market leader in diagnostic products for blood transfusions, with a market value of over $1 billion
	Pursuant to the adoption of FAS 142, Immucor is required to test its goodwill balances, which total $27 million, for impairment
	Immucor retained TM Capital to prepare a valuation analysis of each of its global divisions with goodwill balances
	TM Capital provided Immucor with its opinion that Immucor's goodwill balances are not currently subject to impairment